Key points are not available for this paper at this time.
Sparse randomized data limit antipsychotic confidence for dementia behaviors; leaves open net benefit pending new trials.
Uncontrolled reports suggest that 25% to 75% of patients with behavioral disturbances of dementia respond to conventional neuroleptic drugs. Yet during the past 20 years, results from only four randomized, double-blind, placebo-controlled trials of neuroleptics in dementia have been published. These studies were conducted in hospitalized inpatients or nursing home residents.
No takes yet. Share an insight, caveat, or question.
Davangere P. Devanand (1997) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: